Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
AOC 1020 achieves primary endpoint in FORTITUDE Phase 1/2 trial?  | Binary | 5 | 7 months ago | ||
Avidity Biosciences stock price at year-end 2024 | Categorical | 5 | 7 months ago | ||
Avidity Biosciences receives FDA Fast Track designation for AOC 1020? | Binary | 4 | 7 months ago | ||
Avidity Biosciences partners with a major pharmaceutical company for AOC 1020? | Binary | 4 | 7 months ago | ||
Percentage reduction in DUX4 regulated genes in FORTITUDE Phase 1/2 trial | Categorical | 3 | 7 months ago | ||
Number of patients showing functional improvement in FORTITUDE Phase 1/2 trial | Categorical | 3 | 7 months ago |